Pfizer Inc. (NYSE:PFE) Shares Acquired by Bruce & Co. Inc.

Bruce & Co. Inc. lifted its stake in Pfizer Inc. (NYSE:PFE) by 2.9% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 276,400 shares of the biopharmaceutical company’s stock after acquiring an additional 7,900 shares during the quarter. Pfizer accounts for 2.5% of Bruce & Co. Inc.’s investment portfolio, making the stock its 13th largest position. Bruce & Co. Inc.’s holdings in Pfizer were worth $7,734,000 as of its most recent filing with the SEC.

Other hedge funds have also recently made changes to their positions in the company. Olistico Wealth LLC purchased a new stake in Pfizer during the second quarter worth about $25,000. MFA Wealth Advisors LLC acquired a new stake in Pfizer during the 2nd quarter worth approximately $29,000. Creekmur Asset Management LLC purchased a new position in Pfizer in the 4th quarter valued at approximately $32,000. Trivant Custom Portfolio Group LLC grew its stake in shares of Pfizer by 100.0% in the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 600 shares in the last quarter. Finally, Financial Connections Group Inc. purchased a new stake in Pfizer during the 2nd quarter worth about $34,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 0.4 %

NYSE:PFE opened at $29.27 on Monday. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. The stock’s 50 day simple moving average is $29.21 and its 200-day simple moving average is $28.13. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $34.42. The firm has a market cap of $165.86 billion, a P/E ratio of -487.83, a PEG ratio of 1.04 and a beta of 0.68.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. The company had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. Pfizer’s quarterly revenue was up 2.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.67 EPS. Equities analysts anticipate that Pfizer Inc. will post 2.66 EPS for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 3rd. Investors of record on Friday, July 26th were issued a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 5.74%. The ex-dividend date was Friday, July 26th. Pfizer’s dividend payout ratio is presently -2,800.00%.

Analyst Upgrades and Downgrades

PFE has been the topic of a number of analyst reports. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Monday, September 9th. UBS Group lifted their price target on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 31st. Wells Fargo & Company upped their price objective on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Finally, Barclays upped their target price on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. Eight equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $34.54.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.